TW202239386A - Contact lens product - Google Patents
Contact lens product Download PDFInfo
- Publication number
- TW202239386A TW202239386A TW111103008A TW111103008A TW202239386A TW 202239386 A TW202239386 A TW 202239386A TW 111103008 A TW111103008 A TW 111103008A TW 111103008 A TW111103008 A TW 111103008A TW 202239386 A TW202239386 A TW 202239386A
- Authority
- TW
- Taiwan
- Prior art keywords
- contact lens
- ccu
- cao
- curcumin
- formula
- Prior art date
Links
Images
Landscapes
- Eyeglasses (AREA)
- Control And Other Processes For Unpacking Of Materials (AREA)
Abstract
Description
本發明係關於一種隱形眼鏡產品,特別是有關於一種有助減少雜散光線並消除眩光的隱形眼鏡產品。The present invention relates to a contact lens product, and more particularly to a contact lens product that helps reduce stray light and eliminate glare.
一般隱形眼鏡為達到保護眼睛避免強能量光線傷害,雖有傳統技術使用化學合成紫外光/藍光吸收劑以達到阻隔效果,但由於傳統光吸收劑接觸到眼睛會容易引起不適,過多的劑量甚至會引發嚴重之眼睛的免疫反應或毒物傷害,但一般薑黃素(curcumin, (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione)無法與隱形眼鏡單體有良好鍵結效果,導致容易從隱形眼鏡中釋出,甚至無法克服高溫高壓的滅菌過程而導致分解。In order to protect the eyes from strong energy light damage, general contact lenses use chemically synthesized UV/blue light absorbers to achieve the blocking effect in the traditional technology, but because the traditional light absorbers touch the eyes, they will easily cause discomfort, and excessive doses may even cause Cause serious eye immune reaction or poison damage, but the general curcumin (curcumin, (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione ) cannot have a good bonding effect with the contact lens monomer, resulting in easy release from the contact lens, and even failure to overcome the high temperature and high pressure sterilization process to cause decomposition.
依據本發明提供一種隱形眼鏡產品,包含一隱形眼鏡以及一緩衝溶液。隱形眼鏡保存於緩衝溶液中,其中緩衝溶液包含至少一抗氧化劑。隱形眼鏡包含至少一薑黃素衍生物,所述之薑黃素衍生物具有如式(I)或式(II)所示之一結構:
藉此,本發明之隱形眼鏡產品設計為包含經由改質天然薑黃素所得之具有高單體鍵結效率的新穎薑黃素衍生物,且本發明之薑黃素衍生物具吸收光線並快速變色的效果,有助於高效吸收環境高能量紫外光或藍光光線並轉化成弱能量光線,可有效保護視網膜並減少傷害。再者,本發明之隱形眼鏡產品進一步設計具有適當濃度的抗氧化劑,以克服隱形眼鏡產品因高溫高壓滅菌而破壞薑黃素衍生物之穩定性的問題,而緩衝溶液內的最佳抗氧化物濃度組合,可有效穩定與延長本發明之薑黃素衍生物應有的吸收效用,以完整發揮隱形眼鏡的抗強光保護效果。Therefore, the contact lens product of the present invention is designed to contain novel curcumin derivatives with high monomer bonding efficiency obtained by modifying natural curcumin, and the curcumin derivatives of the present invention have the effect of absorbing light and changing color quickly , helps to efficiently absorb high-energy ultraviolet light or blue light from the environment and convert it into weak energy light, which can effectively protect the retina and reduce damage. Furthermore, the contact lens product of the present invention is further designed to have an appropriate concentration of antioxidants to overcome the problem that contact lens products destroy the stability of curcumin derivatives due to high temperature and high pressure sterilization, and the optimal antioxidant concentration in the buffer solution The combination can effectively stabilize and prolong the absorption effect of the curcumin derivatives of the present invention, so as to fully exert the anti-glare protection effect of contact lenses.
請參照第1圖,其係繪示本發明一實施方式的一種隱形眼鏡產品100的示意圖。隱形眼鏡產品100包含一隱形眼鏡110以及一緩衝溶液120。隱形眼鏡110保存於緩衝溶液120中,且緩衝溶液120包含至少一抗氧化劑(Antioxidant)。Please refer to FIG. 1 , which is a schematic diagram of a
隱形眼鏡110包含至少一薑黃素衍生物(Curcuminoid),所述之薑黃素衍生物具有如式(I)或式(II)所示之一結構:
在本發明的隱形眼鏡產品100中,薑黃素衍生物於隱形眼鏡110中的重量百分比濃度為Ccu,抗氧化劑於緩衝溶液120中的重量百分比濃度為Cao,其滿足下列條件:0.01 ≤ Ccu/Cao ≤ 10.00。或者,其可滿足下列條件:0.02 ≤ Ccu/Cao ≤ 8.00。或者,其可滿足下列條件:0.03 ≤ Ccu/Cao ≤ 3.00。或者,其可滿足下列條件:0.04 ≤ Ccu/Cao ≤ 1.00。或者,其可滿足下列條件:0.05 ≤ Ccu/Cao ≤ 0.70。In the
藉此,本發明之隱形眼鏡產品100的隱形眼鏡110設計為包含至少一種經由改質天然薑黃素所得之具有高單體鍵結效率的新穎薑黃素衍生物,且本發明之薑黃素衍生物具吸收光線並快速變色的效果,有助於高效吸收環境高能量紫外光或藍光光線並轉化成弱能量光線,可有效保護視網膜並減少傷害。再者,本發明之隱形眼鏡產品100進一步設計具有適當濃度的抗氧化劑,以克服隱形眼鏡產品100因高溫高壓滅菌而破壞薑黃素衍生物之穩定性的問題,而緩衝溶液120內的最佳抗氧化物濃度組合,可有效穩定與延長本發明之薑黃素衍生物應有的吸收效用,以完整發揮隱形眼鏡110的抗強光保護效果。再者,本發明之隱形眼鏡110的薑黃素衍生物亦可混合色料以達所需顏色變化,進而應用於具減緩、控制視力的多焦點隱形眼鏡,使其具有可助於減少雜散光線以消除眩光的效果,而搭配調整適當濃度更可阻擋強光以發揮高效遮光效果,但本發明並不以此為限。Thereby, the
在本發明的隱形眼鏡產品100中,式(I)之薑黃素衍生物的R
1與R
2中至少一者可為甲基丙烯酸羥乙酯,式(II)之薑黃素衍生物的R
3與R
4中至少一者可為甲基丙烯酸羥乙酯。藉此,可增加薑黃素衍生物於隱形眼鏡110製作時的相容性,使單體材料可與薑黃素衍生物直接鍵結,並具有良好單體鍵結效率。
In the
在本發明的隱形眼鏡產品100中,式(II)之薑黃素衍生物的R
5可為甲基丙烯酸或2-甲基-2-丙烯酸-2,3-二羥基丙酯。藉此,可具較佳單體鍵結效率,有助於提升薑黃素衍生物與單體材料的鍵結相容性。
In the
在本發明的隱形眼鏡產品100中,薑黃素衍生物於隱形眼鏡110中的重量百分比濃度為Ccu,其可滿足下列條件:0.01% ≤ Ccu ≤ 5.00%。藉此,可有效延長本發明之包含薑黃素衍生物的隱形眼鏡110的高能量波長吸收效果。或者,其可滿足下列條件:0.02% ≤ Ccu ≤ 4.00%。或者,其可滿足下列條件:0.03% ≤ Ccu ≤ 3.00%。或者,其可滿足下列條件:0.04% ≤ Ccu ≤ 2.00%。或者,其可滿足下列條件:0.04% ≤ Ccu ≤ 1.00%。In the
在本發明的隱形眼鏡產品100中,抗氧化劑於緩衝溶液120中的重量百分比濃度為Cao,其可滿足下列條件:0.05% ≤ Cao ≤ 5.00%。藉此,可有效延長本發明之包含薑黃素衍生物的隱形眼鏡110的高能量波長吸收效果。或者,其可滿足下列條件:0.06% ≤ Cao ≤ 4.00%。或者,其可滿足下列條件:0.07% ≤ Cao ≤ 3.00%。或者,其可滿足下列條件:0.08% ≤ Cao ≤ 2.00%。或者,其可滿足下列條件:0.09% ≤ Cao ≤ 1.50%。In the
在本發明的隱形眼鏡產品100中,緩衝溶液120可更包含至少一濕潤劑(Wetting agent),濕潤劑配置於緩衝溶液120中,濕潤劑的重量百分比濃度為Cad,所述濃度定義為任一種濕潤劑的重量百分比濃度,其可滿足下列條件:0.001% ≤ Cad ≤ 1.00%。藉此,可有效提供隱形眼鏡110的保濕與潤滑效果。或者,其可滿足下列條件:0.01% ≤ Cad ≤ 0.50%。In the
在本發明的隱形眼鏡產品100中,薑黃素衍生物的分子量為Wmc,其可滿足下列條件:400 ≤ Wmc ≤ 800。藉此,藉由最佳薑黃素衍生物的結構組合,可維持薑黃素衍生物的吸收效果並提升單體鍵結效率。或者,其可滿足下列條件:410 ≤ Wmc ≤ 750。或者,其可滿足下列條件:420 ≤ Wmc ≤ 700。或者,其可滿足下列條件:430 ≤ Wmc ≤ 600。或者,其可滿足下列條件:450 ≤ Wmc ≤ 500。In the
在本發明的隱形眼鏡產品100中,在隱形眼鏡110經滅菌處理後至少一天,隱形眼鏡110於波長280 nm~310 nm的平均穿透率為T2831,其可滿足下列條件:50% ≤ T2831 ≤ 90%。藉此,適當調整薑黃素衍生物的使用量,可有效提升隱形眼鏡110於UVB範圍的吸收效果。或者,其可滿足下列條件:60% ≤ T2831 ≤ 88%。或者,其可滿足下列條件:70% ≤ T2831 ≤ 86%。或者,其可滿足下列條件:72% ≤ T2831 ≤ 80%。In the
在本發明的隱形眼鏡產品100中,在隱形眼鏡110經滅菌處理後至少一天,隱形眼鏡110於波長310 nm~380 nm的平均穿透率為T3138,其可滿足下列條件:60% ≤ T3138 ≤ 92%。藉此,適當調整薑黃素衍生物的使用量,可有效提升隱形眼鏡110於UVA範圍的吸收效果。或者,其可滿足下列條件:60% ≤ T3138 ≤ 85%。或者,其可滿足下列條件:75% ≤ T3138 ≤ 85%。In the
在本發明的隱形眼鏡產品100中,在隱形眼鏡110經滅菌處理後至少一天,隱形眼鏡110於波長410 nm~460 nm的平均穿透率為T4146,其可滿足下列條件:70% ≤ T4146 ≤ 90%。藉此,適當調整薑黃素衍生物的使用量,可有效提升隱形眼鏡110於藍光範圍的吸收效果。或者,其可滿足下列條件:75% ≤ T4146 ≤ 85%。或者,其可滿足下列條件:80% ≤ T4146 ≤ 90%。In the
在本發明的隱形眼鏡產品100中,在隱形眼鏡110經滅菌處理後至少一天,隱形眼鏡110於波長460 nm~780 nm的平均穿透率為T4678,其可滿足下列條件:90% ≤ T4678 ≤ 98%。藉此,適當調整薑黃素衍生物的使用量,可有效維持隱形眼鏡110的高透光效果。In the
在本發明的隱形眼鏡產品100中,在隱形眼鏡110經滅菌處理後至少一天,隱形眼鏡110於波長380 nm~780 nm的平均穿透率為T3878,其可滿足下列條件:85% ≤ T3878 ≤ 98%。藉此,適當調整薑黃素衍生物的使用量,可有效平衡隱形眼鏡110的薑黃素衍生物的吸收與高透光效果。In the
在本發明的隱形眼鏡產品100中,在隱形眼鏡110經滅菌處理後至少一天,隱形眼鏡110於波長280 nm~310 nm的吸收阻隔效率為BE2831,其可滿足下列條件:4.0% ≤ BE2831 ≤ 50.0%。藉此,可有效維持隱形眼鏡110的高能量UVB光線的吸收效果。或者,其可滿足下列條件:5.0% ≤ BE2831 ≤ 50.0%。或者,其可滿足下列條件:5.0% ≤ BE2831 ≤ 40.0%。或者,其可滿足下列條件:6.0% ≤ BE2831 ≤ 30.0%。或者,其可滿足下列條件:7.5% ≤ BE2831 ≤ 20.0%。或者,其可滿足下列條件:10.0% ≤ BE2831 ≤ 50.0%。In the
在本發明的隱形眼鏡產品100中,在隱形眼鏡110經滅菌處理後至少一天,隱形眼鏡110於波長310 nm~380 nm的吸收阻隔效率為BE3138,其可滿足下列條件:3.0% ≤ BE3138 ≤ 35.0%。藉此,可有效維持隱形眼鏡110的高能量UVA光線的吸收效果。或者,其可滿足下列條件:3.5% ≤ BE3138 ≤ 30.0%。或者,其可滿足下列條件:5.0% ≤ BE3138 ≤ 35.0%。或者,其可滿足下列條件:7.5% ≤ BE3138 ≤ 35.0%。或者,其可滿足下列條件:10.0% ≤ BE3138 ≤ 20.0%。In the
在本發明的隱形眼鏡產品100中,在隱形眼鏡110經滅菌處理後至少一天,隱形眼鏡110於波長410 nm~460 nm的吸收阻隔效率為BE4146,其可滿足下列條件:1.0% ≤ BE4146 ≤ 30.0%。藉此,可有效維持隱形眼鏡110的高能量藍光光線的吸收效果。或者,其可滿足下列條件:1.5% ≤ BE4146 ≤ 27.0%。或者,其可滿足下列條件:2.0% ≤ BE4146 ≤ 25.0%。或者,其可滿足下列條件:2.5% ≤ BE4146 ≤ 23.0%。或者,其可滿足下列條件:5.0% ≤ BE4146 ≤ 20.0%。In the
在本發明的隱形眼鏡產品100中,在隱形眼鏡110經滅菌處理後至少一天,隱形眼鏡110於波長460 nm~780 nm的吸收阻隔效率為BE4678,其可滿足下列條件:0.5% ≤ BE4678 ≤ 5.0%。藉此,可有效維持隱形眼鏡110的高透光效果。In the
在本發明的隱形眼鏡產品100中,在隱形眼鏡110經滅菌處理後至少一天,隱形眼鏡110於波長380 nm~780 nm的吸收阻隔效率為BE3878,其可滿足下列條件:1.0% ≤ BE3878 ≤ 10.0%。藉此,可有效平衡隱形眼鏡110的薑黃素衍生物的吸收與高透光效果。In the
在本發明的隱形眼鏡產品100中,隱形眼鏡110可包含至少二薑黃素衍生物。藉此,可依所需變色效果調整選用薑黃素衍生物,且多種薑黃素衍生物混用可達到不同的顏色變化表現。In the
在本發明的隱形眼鏡產品100中,隱形眼鏡110可更包含至少一色料。藉此,本發明之隱形眼鏡110的變色區將可包含薑黃素衍生物的混合色料,使變色區依所需達到不同的顏色變化,若變色區設計為小於光學區的環狀,將有助於達到減少雜散光線,使其在應用於具減緩、控制視力的多焦點隱形眼鏡時,具有消除眩光效果。或者,若變色區設計為圓盤狀且覆蓋光學區域,則可阻擋強光以發揮如墨鏡的減光效果。或者,若進一步將變色區設計在非光學區的外部區域,則具有調整隱形眼鏡110的外觀而達成虹膜放大的效果。In the
再者,在本發明的隱形眼鏡產品100中,隱形眼鏡110的色料可形成一圖樣。圖樣可包含文字、數字或圖案,可具指向性與代表性功能,並可產生辨識標記、效期指示、方向辨識、指示環境可能危害狀態等效果。Furthermore, in the
在本發明的隱形眼鏡產品100中,隱形眼鏡110可包含至少三鏡片層。藉此,可避免色料於隱形眼鏡110中漏出,減少化學物質與眼睛接觸的機會。In the
在本發明的隱形眼鏡產品100中,隱形眼鏡產品100為一日拋式產品,且隱形眼鏡產品100可更包含一避光包裝。詳細而言,薑黃素衍生物經光線照射後可能會隨時間而衰退發光效果,因此需在薑黃素衍生物具有最大活性的效期內使用,以維持最佳遮光或減光效果,而以完全避光的包裝阻隔光線,可保護並維持隱形眼鏡110內的薑黃素衍生物,有助長時間保存並維持最佳遮光或減光效果。In the
本發明的隱形眼鏡產品100是由以下步驟製得:(1) 將未改質薑黃素以特定合成步驟,合成出改質薑黃素。(2) 將改質薑黃素添加至特定配方單體中均勻混合。(3) 將單體混合物均質化後以UV/熱進行固化,以製成隱形眼鏡110。(4) 隱形眼鏡110的成品將以水化步驟處理並保存於緩衝溶液120中。(5) 將包含隱形眼鏡110與緩衝溶液120的密封包裝以121°C的條件高溫滅菌至少20分鐘,即得本發明之隱形眼鏡產品100。The
在本發明的隱形眼鏡產品100中,隱形眼鏡110於特定波長範圍的穿透率測量步驟如下:(1) 將隱形眼鏡110平衡於標準液中。(2) 將隱形眼鏡110連同標準液置於石英盤中,並在掃描精準度為1 nm、掃描範圍為200 nm~800 nm的條件下以儀器量測隱形眼鏡110的穿透率。In the
上述本發明之隱形眼鏡產品中的各技術特徵皆可組合配置,而達到對應之功效。All the technical features of the above-mentioned contact lens product of the present invention can be combined and configured to achieve corresponding effects.
本發明中所述隱形眼鏡的功能可為近視(Myopia)矯正、遠視(Hyperopia)矯正、老花(Presbyopia)矯正、散光(Astigmatism)矯正、近視控制延緩(Myopia control)、角膜塑型(Corneal reshaping)等。The functions of the contact lens in the present invention can be Myopia correction, Hyperopia correction, Presbyopia correction, Astigmatism correction, Myopia control delay, Corneal reshaping )Wait.
本發明中所述隱形眼鏡的屈光度(Diopter)以D值表示,例如矯正近視的鏡片中心屈光度為負值,矯正遠視的鏡片中心屈光度為正值。本發明中所述近視加重即意指近視度數加深,負屈光度的絕對值數值越大,如-0.5 D加重/加深至-2.0 D。The diopter of the contact lens in the present invention is represented by D value, for example, the central diopter of the lens for correcting myopia is a negative value, and the central diopter of a lens for correcting hyperopia is a positive value. The aggravation of myopia in the present invention refers to the deepening of the degree of myopia, and the greater the absolute value of the negative diopter, such as -0.5 D aggravation/deepening to -2.0 D.
本發明中所述隱形眼鏡的面型變化如球面(Spheric)、平面(Plane)或非球面(Aspheric),以過中心剖視的曲面形狀為準。本發明中所述隱形眼鏡的前表面(Front surface)指遠離眼球角膜的表面,後表面(Back surface)指靠近眼球角膜的表面。The surface shape of the contact lens described in the present invention changes, such as spherical (Spheric), plane (Plane) or aspheric (Aspheric), and the shape of the curved surface viewed through the center shall prevail. The front surface (Front surface) of the contact lens in the present invention refers to the surface away from the cornea of the eyeball, and the back surface (Back surface) refers to the surface close to the cornea of the eyeball.
本發明中所述隱形眼鏡的穩定結構可具有旋轉穩定設計,如下部增厚垂重設計、兩側增厚的平衡設計、不對稱平衡設計與上下削薄穩定設計等。The stable structure of the contact lens in the present invention can have a rotationally stable design, such as a thickened and vertically heavy design at the bottom, a balanced design with thickened sides, an asymmetric balanced design, and a stable design with thinned top and bottom.
本發明中所述隱形眼鏡的結構組成可為至少兩層鏡片;其中彩色隱形眼鏡可為二層組成,如鏡片本體層和色彩層;彩色隱形眼鏡可為三層組成,如鏡片本體層、色彩層與防脫落保護層;彩色隱形眼鏡可為四層組成,如鏡片本體層、第一色彩層、第二色彩層與防脫落保護層。彩色隱形眼鏡可為五層組成,如鏡片本體層、第一色彩層、第二色彩層、第三色彩層與防脫落保護層。彩色隱形眼鏡可為另一種五層組成,如鏡片本體層、第一色彩層、分隔層、第二色彩層與防脫落保護層。The structural composition of the contact lenses described in the present invention can be at least two layers of lenses; wherein the colored contact lenses can be composed of two layers, such as the lens body layer and the color layer; the colored contact lenses can be composed of three layers, such as the lens body layer, the color layer layer and anti-shedding protective layer; colored contact lenses can be composed of four layers, such as lens body layer, first color layer, second color layer and anti-shedding protective layer. The color contact lens can be composed of five layers, such as a lens body layer, a first color layer, a second color layer, a third color layer and an anti-shedding protective layer. The colored contact lens can be composed of another five layers, such as a lens body layer, a first color layer, a separation layer, a second color layer and an anti-shedding protective layer.
本發明中所述隱形眼鏡的組成物包含至少二種單體、至少一種交聯劑、至少一種稀釋劑、至少一種起始劑,以及選擇性地包含紫外光吸收劑或藍光吸收劑。藉此,可選擇並調整組成物中各成分的種類與含量,有助於調整隱形眼鏡的彈性係數並影響隱形眼鏡的軟硬度,進而提升耐用性與穩定度,並可調控最適當的隱形眼鏡含水量以增加舒適性與透氧率。組成物包含可至少四種單體、至少二種交聯劑、至少二種稀釋劑、至少一種起始劑,以及選擇性地包含紫外光吸收劑或藍光吸收劑。藉此,可製備出同時包含第一材質與第二材質的隱形眼鏡。The composition of the contact lens in the present invention includes at least two monomers, at least one crosslinking agent, at least one diluent, at least one initiator, and optionally includes an ultraviolet light absorber or a blue light absorber. In this way, the type and content of each component in the composition can be selected and adjusted, which helps to adjust the elastic coefficient of the contact lens and affect the hardness of the contact lens, thereby improving durability and stability, and can regulate the most appropriate contact lens. The glasses contain moisture to increase comfort and oxygen permeability. The composition includes at least four monomers, at least two cross-linking agents, at least two diluents, at least one initiator, and optionally includes an ultraviolet light absorber or a blue light absorber. In this way, a contact lens containing both the first material and the second material can be prepared.
本發明中所述隱形眼鏡的水膠單體可包含:甲基丙烯酸羥乙酯(HEMA;2-Hydroxyethyl methacrylate)、甲基丙烯酸(MAA;Methacrylic Acid)、2-甲基-2-丙烯酸-2,3-二羥基丙酯(GMA;Glycerol monomethacrylate)、N-乙烯基-2-吡咯酮(NVP;N-Vinyl-2-pyrrolidinone),甲基丙烯酸甲酯(MMA;Methyl methacrylate)、N,N-二甲基丙烯醯胺(DMAA;N,N-Dimethyl Acrylamide)等。藉此,有助於維持濕潤、滑順與柔軟舒適的水潤感,能夠長時間配戴,避免配戴時的異物感。The hydrogel monomer of the contact lens described in the present invention may comprise: hydroxyethyl methacrylate (HEMA; 2-Hydroxyethyl methacrylate), methacrylic acid (MAA; Methacrylic Acid), 2-methyl-2-acrylic acid-2 ,3-dihydroxypropyl ester (GMA; Glycerol monomethacrylate), N-vinyl-2-pyrrolone (NVP; N-Vinyl-2-pyrrolidinone), methyl methacrylate (MMA; Methyl methacrylate), N,N -Dimethacrylamide (DMAA; N,N-Dimethyl Acrylamide) and the like. In this way, it helps to maintain a moist, smooth, soft and comfortable hydration feeling, and can be worn for a long time to avoid foreign body sensation when worn.
本發明中所述隱形眼鏡的水膠可為但不限於經美國食品藥物管理局歸類至第1群組隱形眼鏡材料,即低含水量(小於50重量百分比)的非離子型聚合物(nonionic polymer),如Helfilcon A&B、Hioxifilcon B、Mafilcon、Polymacon、Tefilcon、Tetrafilcon A等。或者,前述水膠可為經美國食品藥物管理局歸類至第2群組隱形眼鏡材料,即高含水量(大於50重量百分比)的非離子型聚合物,如Acofilcon A、Alfafilcon A、Hilafilcon B、Hioxifilcon A、Hioxifilcon B、Hioxifilcon D、Nelfilcon A、Nesofilcon A、Omafilcon A及Samfilcon A等。或者,前述水膠可為經美國食品藥物管理局歸類至第3群組隱形眼鏡材料,即低含水量(小於50重量百分比)的離子型聚合物(ionic polymer),如Deltafilcon A等。或者,前述水膠可為經美國食品藥物管理局歸類的第4群組隱形眼鏡材料、即高含水量(大於50重量百分比)的離子型聚合物,如Etafilcon A、Focofilcon A、Methafilcon A、Methafilcon B、Ocufilcon A、Ocufilcon B、Ocufilcon C、Ocufilcon D、Ocufilcon E、Phemfilcon A、Vifilcon A等。The hydrogel of the contact lens in the present invention can be, but not limited to, the contact lens material classified into
本發明中所述隱形眼鏡的矽水膠單體可為但不限於甲基丙烯酸羥乙酯(2-hydroxyethyl methacrylate)、2-甲基-2-丙烯酸-2,3-二羥基丙酯(glycerol monomethacrylate)、甲基丙烯酸(methacrylic acid)、甲基丙烯醯氧丙基三(三甲基矽氧烷基)矽烷(3-methacryloyloxypropyltris(trimethylsilyloxy) silane)、N-乙烯基-2-吡咯酮(N-vinyl-2-pyrrolidinone)、N,N-二甲基丙烯醯胺(N,N-dimethyl acrylamide)、(3-甲基丙烯醯氧基-2-羥基丙氧基)丙基雙(三甲基矽氧基)甲基(3-(3-methacryloxy-2-hydroxypropoxy)propylbis(trimethylsiloxy)methylsilane)或3-乙醯氧基-2-羥基丙氧基丙基封端的聚二甲基矽氧烷((3-acryloxy-2-hydroxypropoxypropyl) terminated polydimethylsiloxane)。藉此,可選擇最適當單體種類,有助於使設計的隱形眼鏡在耐用性、穩定度、舒適性與透氧率等參數間的平衡配置,可有效提高透氧率而避免因角膜缺氧引起的紅眼血絲、紅腫等現象以提供長時間配戴的舒適感。The silicon hydrogel monomer of the contact lens described in the present invention can be but not limited to hydroxyethyl methacrylate (2-hydroxyethyl methacrylate), 2-methyl-2-acrylic acid-2,3-dihydroxypropyl ester (glycerol monomethacrylate), methacrylic acid (methacrylic acid), methacryloxypropyl tris (trimethylsiloxane) silane (3-methacryloyloxypropyltris (trimethylsilyloxy) silane), N-vinyl-2-pyrrolone (N -vinyl-2-pyrrolidinone), N,N-dimethyl acrylamide (N,N-dimethyl acrylamide), (3-methacryloxy-2-hydroxypropoxy) propyl bis (trimethyl 3-(3-methacryloxy-2-hydroxypropoxy)propylbis(trimethylsiloxy)methylsilane) or 3-acetyloxy-2-hydroxypropoxypropyl terminated polydimethylsiloxane ((3-acryloxy-2-hydroxypropoxypropyl) terminated polydimethylsiloxane). In this way, the most appropriate type of monomer can be selected, which helps to make the designed contact lens balance configuration among parameters such as durability, stability, comfort and oxygen transmission rate, and can effectively improve the oxygen transmission rate and avoid corneal defects. Red eyes, bloodshot eyes, redness and swelling caused by oxygen to provide long-term wearing comfort.
本發明中所述隱形眼鏡的矽水膠可為但不限於經美國食品藥物管理局(USFDA)歸類至第5群組隱形眼鏡材料,如Balafilcon A、Comfilcon A、Efrofilcon A、Enfilcon A、Galyfilcon A、Lotrafilcon A、Lotrafilcon B、Narafilcon A、Narafilcon B、Senofilcon A、Delefilcon A、Somofilcon A等。The silicone hydrogel of the contact lens in the present invention can be, but not limited to, classified into
本發明中所述隱形眼鏡的產品可由隱形眼鏡本體、溶液與包裝組成,隱形眼鏡本體或溶液中可包含:單體(Monomer)、UV吸收劑(UV Absorber)、藍光吸收劑(Blue Absorber)、助益劑(Beneficial agents)、濕潤劑(Wetting agent)、色素(Dye)、近視控制藥劑(Myopia control agent)、弱酸及其共軛鹼的鹽類(Acid and its conjugate base)、弱鹼及其共軛酸的鹽類(Base and its conjugate acid)、陰離子劑(Anionic agent)、陽離子劑(Cationic agent)及其他助益劑;本發明包裝可由塑膠容器與鋁箔上蓋組合製作,塑膠容器可由聚丙烯(PP;Polypropylene)、聚苯乙烯(PS;Polystyrene)、聚對苯二甲酸乙二酯(PET;Polyethylene terephthalate)或其他塑膠材料,亦可使用生物可分解塑膠(Biodegradable plastic)製作,如含PLA(Polylactic Acid)、PHA(polyhydroxyalkanoates)或其他可分解塑膠等,生物可分解塑膠亦可混製生物可分解塑化劑(Biodegradable plasticizer)以達到改質或改性效果;本發明鋁箔上蓋可為具塑膠塗層的複合鋁箔材質。The product of the contact lens described in the present invention may be composed of a contact lens body, a solution and a package, and the contact lens body or solution may include: a monomer (Monomer), a UV absorber (UV Absorber), a blue light absorber (Blue Absorber), Beneficial agents, Wetting agent, Dye, Myopia control agent, Acid and its conjugate base, Weak base and its conjugate base Conjugate acid salt (Base and its conjugate acid), anionic agent (Anionic agent), cationic agent (Cationic agent) and other beneficial agents; the packaging of the present invention can be made of a combination of plastic container and aluminum foil cover, and the plastic container can be made of polypropylene (PP; Polypropylene), polystyrene (PS; Polystyrene), polyethylene terephthalate (PET; Polyethylene terephthalate) or other plastic materials can also be made of biodegradable plastic, such as PLA (Polylactic Acid), PHA (polyhydroxyalkanoates) or other degradable plastics, etc. Biodegradable plastics can also be mixed with biodegradable plasticizers (Biodegradable plasticizer) to achieve modification or modification effects; the aluminum foil cover of the present invention can be a Plastic-coated composite aluminum foil material.
本發明中所述隱形眼鏡的起始劑可為但不限於2-羥基-2-甲基-1-苯基-1-丙酮(2-hydroxy-2-methyl-propiophenone)。藉此,可有效使隱形眼鏡的組成物有效達成高效率的聚合反應。The initiator of the contact lens in the present invention may be but not limited to 2-hydroxy-2-methyl-1-phenyl-1-propanone (2-hydroxy-2-methyl-propiophenone). Thereby, the composition of the contact lens can effectively achieve high-efficiency polymerization reaction.
本發明中所述隱形眼鏡的交聯劑可為但不限於二甲基丙烯酸乙二醇酯(ethylene glycol dimethacrylate)或三羥甲基丙烷三甲基丙烯酸酯(1,1,1-trimethylol propane trimethacrylate)。藉此,可有效使單體間獲得良好的交聯效果,提升隱形眼鏡的穩定度與耐用性。The cross-linking agent of contact lens described in the present invention can be but not limited to ethylene glycol dimethacrylate (ethylene glycol dimethacrylate) or trimethylolpropane trimethacrylate (1,1,1-trimethylol propane trimethacrylate ). Thereby, a good cross-linking effect between the monomers can be effectively obtained, and the stability and durability of the contact lens can be improved.
本發明中所述隱形眼鏡的稀釋劑可為聚乙二醇 300(polyethylene glycol 300)、聚乙二醇 600(polyethylene glycol 600)、聚乙二醇 800(polyethylene glycol 800)、聚乙二醇 1000(polyethylene glycol 1000)、聚乙二醇 2000(polyethylene glycol 2000)、聚乙二醇 4000(polyethylene glycol 4000)、1,4-丁二醇(1,4-butanediol)、乙醇(ethanol)、異丙醇(isopropyl alcohol)、甘油(glycerol)或正己醇(1-hexanol)。藉此,可輔助調整隱形眼鏡的彈性係數,以提高隱形眼鏡配戴的舒適性。The diluent of contact lens described in the present invention can be polyethylene glycol 300 (polyethylene glycol 300), polyethylene glycol 600 (polyethylene glycol 600), polyethylene glycol 800 (polyethylene glycol 800), polyethylene glycol 1000 (polyethylene glycol 1000), polyethylene glycol 2000 (polyethylene glycol 2000), polyethylene glycol 4000 (polyethylene glycol 4000), 1,4-butanediol (1,4-butanediol), ethanol (ethanol), isopropyl Alcohol (isopropyl alcohol), glycerol (glycerol) or n-hexanol (1-hexanol). Thereby, the elastic coefficient of the contact lens can be assisted to be adjusted, so as to improve the wearing comfort of the contact lens.
本發明中所述隱形眼鏡的紫外光(Ultraviolet,UV)吸收劑可為但不限於2-[3-(2H-苯並三唑-2-基)-4-羥基苯基]乙基2-甲基丙烯酸(2-[3-(2H-benzotriazol-2-yl)-4-hydroxyphenyl]ethyl methacrylate)、4-甲基丙烯醯氧基-2-羥基二苯甲酮(4-methacryloxy-2-hydroxybenzophenone)、2-苯基乙基丙烯酸酯(2-phenylethyl acrylate)、2-甲基丙烯酸苯乙烯酯(2-phenylethyl methacrylate)、2-[2-羥基-5-[2-(甲基丙烯醯氧)乙基]苯基]-2H-苯並三唑(2-(2'-hydroxy-5'-methacryloxyethylphenyl)-2H-benzotriazole)或2-丙烯酸 2-(4-苯甲醯-3-羥基苯氧基)乙基酯(2-(4-benzoyl-3-hydroxyphenoxy) ethyl acrylate)。藉此,隱形眼鏡可吸收高能量UV光,進而可降低視網膜受UV光傷害的機率。The ultraviolet (Ultraviolet, UV) absorber of the contact lens described in the present invention can be but not limited to 2-[3-(2H-benzotriazol-2-yl)-4-hydroxyphenyl] ethyl 2- Methacrylic acid (2-[3-(2H-benzotriazol-2-yl)-4-hydroxyphenyl]ethyl methacrylate), 4-methacryloxy-2-hydroxybenzophenone (4-methacryloxy-2- hydroxybenzophenone), 2-phenylethyl acrylate (2-phenylethyl acrylate), 2-styrene methacrylate (2-phenylethyl methacrylate), 2-[2-hydroxy-5-[2-(methacryl Oxy)ethyl]phenyl]-2H-benzotriazole (2-(2'-hydroxy-5'-methacryloxyethylphenyl)-2H-benzotriazole) or 2-(4-benzoyl-3-hydroxy Phenoxy) ethyl ester (2-(4-benzoyl-3-hydroxyphenoxy) ethyl acrylate). In this way, the contact lens can absorb high-energy UV light, thereby reducing the chance of the retina being damaged by UV light.
本發明中所述隱形眼鏡的藍光吸收劑可為但不限於四苯基二甲基丙烯酸(4-(phenyldiazenyl) phenyl methacrylate)。藉此,隱形眼鏡可吸收高能量藍光,進而可降低視網膜受藍光傷害的機率。The blue light absorbing agent of the contact lens in the present invention can be but not limited to tetraphenyl dimethacrylic acid (4-(phenyldiazenyl) phenyl methacrylate). In this way, the contact lens can absorb high-energy blue light, thereby reducing the chance of the retina being damaged by blue light.
本發明中所述隱形眼鏡的濕潤劑可包含:2-甲基丙烯醯氧乙基磷酸膽鹼(MPC;2–Methacryloyloxyphosphorylcholine)、玻尿酸(Hyaluronic Acid)、海藻酸(Alginic acid)或其鹽類等。The wetting agent of the contact lens in the present invention may include: 2-methacryloxyethylphosphorylcholine (MPC; 2-Methacryloyloxyphosphorylcholine), hyaluronic acid (Hyaluronic Acid), alginic acid (Alginic acid) or its salts, etc. .
本發明中所述隱形眼鏡的色素可包含:花青素(Anthocyanidin)、β胡蘿蔔素(Beta-Carotene)、薑黃素(Curcumin)、螢光素(Luciferin)、葉黃素(Lutein)、茄紅素(Lycopene)、藻膽素(Phycobillin)、藻紅素(Phycoerythrim)、藻藍素(Phycocyanin)、核黃素(Vitamin B2)、玉米黃素(Zeaxanthin)、光致變色劑(Photochromic dyes)、溫致變色劑(Thermochromic dyes)等,及其衍生物。The pigment of the contact lens in the present invention may include: Anthocyanidin, Beta-Carotene, Curcumin, Luciferin, Lutein, Lycopene Lycopene, Phycobillin, Phycoerythrim, Phycocyanin, Vitamin B2, Zeaxanthin, Photochromic dyes, Thermochromic dyes, etc., and their derivatives.
本發明中所述隱形眼鏡的助益劑可包含:抗生素(Antibotic)、抑菌劑(Bacteriostatic agent)、抗病毒劑(Antiviral agent)、抗真菌劑(Antifungal drugs)、抗過敏劑(Antiallergic agent)、阿撲嗎啡(Apomorphine)、溴隱亭(Bromocriptine)、多巴胺接受體促效劑(Dopamine)、左旋多巴(Levodopa)、或喹吡羅(Quinpirole)、類固醇(Steroid)、非類固醇類消炎劑(NSAIDs)、活性劑(Surfactants)、縮瞳劑(Miotics)、酶抑制劑(Enzyme Inhibitor)、麻醉劑(Anaesthetic)、血管收縮劑(Vasoconstrictor)、維生素(Vitamin)、抗氧化劑、營養劑(Nutrient)等。The beneficial agents of the contact lens in the present invention may include: Antibotic, Bacteriostatic agent, Antiviral agent, Antifungal drugs, Antiallergic agent , Apomorphine, Bromocriptine, Dopamine, Levodopa, or Quinpirole, Steroids, NSAIDs (NSAIDs), Surfactants, Miotics, Enzyme Inhibitors, Anaesthetics, Vasoconstrictors, Vitamins, Antioxidants, Nutrients Wait.
本發明中所述隱形眼鏡的抗氧化劑可為維生素A(Vitamin A)、維生素C(Vitamin C)、維生素E(Vitamin E)、尿酸(Uric acid)、類胡蘿蔔素(Carotenoid)、類黃酮化合物(Flavonoids)、白藜蘆醇(Resveratrol)、甲硒胺酸(Selenomethionine)等。The antioxidant of contact lens described in the present invention can be vitamin A (Vitamin A), vitamin C (Vitamin C), vitamin E (Vitamin E), uric acid (Uric acid), carotenoid (Carotenoid), flavonoid compound ( Flavonoids), Resveratrol, Selenomethionine, etc.
本發明中所述隱形眼鏡的近視控制藥劑可包含:睫狀肌麻痺劑、瞳孔放大劑(散瞳劑)、選擇性/非選擇性的蕈毒鹼受體拮抗劑等,具有控制、減緩、延遲或防止近視加重的效果,如可藉由阻斷副交感神經的M型蕈毒鹼受體,鬆弛麻痺控制瞳孔的睫狀肌,進而可放大瞳孔。如阿托品(Atropine;(3-endo)-8-Methyl-8-azabicyclo[3.2.1]oct-3-yltropate)、阿托品硫酸鹽(Atropine sulphate)、環戊醇胺酯(Cyclopentolate;2-(Dimethylamino)ethyl(1-hydroxycyclopentyl)(phenyl)acetate)、鹽酸環戊苯胺酯(Cyclopentolate HCl)、尤卡托品(Eucatropine;1,2,2,6-Tetramethyl-4-piperidinylhydroxy(phenyl)acetate)、后馬托品(Homatropine;(3-endo)-8-Methyl-8-azabicyclo[3.2.1]oct-3-ylhydroxy(phenyl)acetate)、奴文西品(Nuvenzepine)、鹽酸去氧腎上腺素(Phenylephrine HCl)、哌侖西品(Pirenzepine)、消旋山莨菪鹼(Raceanisodamine)、利噴西品(Rispenzepine)、東莨菪鹼(Scopolamine;(1R,2R,4S,5S,7s)-9-Methyl-3-oxa-9-azatricyclo[3.3.1.02,4]non-7-yl(2S)-3-hydroxy-2-phenylpropanoate)、莨菪鹼氫溴酸鹽(Scopolamine HBr)、替侖西品(Telenzepine)和托品卡胺(Tropicamide;N-Ethyl-3-hydroxy-2-phenyl-N-(4-pyridinylmethyl)propanamide)等,及其鹽類。The myopia control agent of the contact lens described in the present invention can comprise: cycloplegic agent, mydriasis agent (mydriatic agent), selective/non-selective muscarinic receptor antagonist etc., have control, slow down, The effect of delaying or preventing the aggravation of myopia, for example, by blocking the M-type muscarinic receptors of the parasympathetic nerve, relaxes and paralyzes the ciliary muscle that controls the pupil, thereby dilating the pupil. Such as atropine (Atropine; (3-endo)-8-Methyl-8-azabicyclo[3.2.1]oct-3-yltropate), atropine sulfate (Atropine sulfate), cyclopentolamine ester (Cyclopentolate; 2-(Dimethylamino )ethyl(1-hydroxycyclopentyl)(phenyl)acetate), Cyclopentolate HCl, Eucatropine (1,2,2,6-Tetramethyl-4-piperidinylhydroxy(phenyl)acetate), later Matropine (Homatropine; (3-endo)-8-Methyl-8-azabicyclo[3.2.1]oct-3-ylhydroxy(phenyl)acetate), Nuvenzepine, Phenylephrine hydrochloride HCl), Pirenzepine, Raceanisodamine, Rispenzepine, Scopolamine; (1R,2R,4S,5S,7s)-9-Methyl-3- oxa-9-azatricyclo[3.3.1.02,4]non-7-yl(2S)-3-hydroxy-2-phenylpropanoate), Scopolamine HBr, Telenzepine and Tropone Picamide (Tropicamide; N-Ethyl-3-hydroxy-2-phenyl-N-(4-pyridinylmethyl)propanamide), etc., and salts thereof.
上述本發明之隱形眼鏡產品中的各技術特徵皆可組合配置,而達到對應之功效。All the technical features of the above-mentioned contact lens product of the present invention can be combined and configured to achieve corresponding effects.
根據上述實施方式,以下提出具體實施例並配合圖式予以詳細說明。According to the above-mentioned implementation manners, specific embodiments are proposed below and described in detail with reference to the drawings.
<第1實施例至第4實施例><First to fourth examples>
在第1實施例至第4實施例的隱形眼鏡產品中,隱形眼鏡的薑黃素衍生物具有如式(1)所示之結構,而關於第1實施例至第4實施例的薑黃素衍生物的詳細內容請參見表一。
在第1實施例至第4實施例的隱形眼鏡產品中,緩衝溶液的抗氧化劑係維生素C,濕潤劑為玻尿酸(Hyaluronic acid, HA)與海藻酸鈉(Sodium Alginate, SA),而關於第1實施例至第4實施例的Ccu、Cao、Cad、Ccu/Cao的數值請參見表二。
<第5實施例至第8實施例><Example 5 to Example 8>
在第5實施例至第8實施例的隱形眼鏡產品中,隱形眼鏡的薑黃素衍生物具有如式(2)所示之結構,而關於第5實施例至第8實施例的薑黃素衍生物的詳細內容請參見表三。
在第5實施例至第8實施例的隱形眼鏡產品中,緩衝溶液的抗氧化劑係維生素C,濕潤劑為玻尿酸與海藻酸鈉,而關於第5實施例至第8實施例的Ccu、Cao、Cad、Ccu/Cao的數值請參見表四。
請參照第2圖至第6圖,第2圖係繪示本發明第5實施例、第7實施例與第1控制組於波長280 nm~310 nm的穿透率數據圖,第3圖係繪示本發明第5實施例、第7實施例與第1控制組於波長310 nm~380 nm的穿透率數據圖,第4圖係繪示本發明第5實施例、第7實施例與第1控制組於波長410 nm~460 nm的穿透率數據圖,第5圖係繪示本發明第5實施例、第7實施例與第1控制組於波長460 nm~780 nm的穿透率數據圖,而第6圖係繪示本發明第5實施例、第7實施例與第1控制組於波長380 nm~780 nm的穿透率數據圖。另外,為了更清楚呈現本發明之隱形眼鏡產品在其緩衝溶液添加抗氧化劑後克服因高溫高壓滅菌而破壞薑黃素衍生物之穩定性的效果,於此進一步提出未包含抗氧化劑之第1控制組,以和第5實施例與第7實施例進行比較說明,其中第1控制組的薑黃素衍生物具有如式(2)所示之結構,且Ccu = 0.05%。Please refer to Figures 2 to 6. Figure 2 shows the transmittance data of the fifth embodiment, the seventh embodiment and the first control group of the present invention at a wavelength of 280 nm to 310 nm, and Figure 3 is It shows the transmittance data graphs of the fifth embodiment, the seventh embodiment and the first control group of the present invention at a wavelength of 310 nm to 380 nm. Figure 4 shows the fifth embodiment, the seventh embodiment and the first control group of the present invention. The transmittance data graph of the first control group at a wavelength of 410 nm to 460 nm. Figure 5 shows the transmittance of the fifth embodiment, the seventh embodiment and the first control group of the present invention at a wavelength of 460 nm to 780 nm Figure 6 is a graph showing the transmittance data of the fifth embodiment, the seventh embodiment and the first control group of the present invention at a wavelength of 380 nm to 780 nm. In addition, in order to more clearly present the effect of the contact lens product of the present invention adding antioxidants to its buffer solution to overcome the effect of destroying the stability of curcumin derivatives due to high temperature and high pressure sterilization, a first control group that does not contain antioxidants is further proposed here , To compare and illustrate with the 5th embodiment and the 7th embodiment, wherein the curcumin derivative of the 1st control group has the structure shown in formula (2), and Ccu=0.05%.
第1控制組、第5實施例與第7實施例的T2831、T3138、T4146、T4678、T3878於滅菌處理前一天(第-1天)、滅菌處理當天(第0天)以及經滅菌處理後十天(第10天)的數值記錄於表五。
另外,於此更進一步根據第1控制組與第5實施例以及第1控制組與第7實施例的T2831、T3138、T4146、T4678、T3878數值計算第5實施例和第7實施例於滅菌處理當天以及經滅菌處理後十天的BE2831、BE3138、BE4146、BE4678、BE3878的數值。詳細而言,本說明書中所指之吸收阻隔效率為包含薑黃素衍生物的隱形眼鏡產品(C)與一般不含薑黃素衍生物的隱形眼鏡產品(nC)在特定波長範圍內的平均穿透率差異百分比。舉例而言,以隱形眼鏡經滅菌處理後第10天於波長280 nm~310 nm的平均穿透率T2831為例計算其於波長280 nm~310 nm的吸收阻隔效率BE2831的方式如下:
BE2831 = (|(C
T2831– nC
T2831)|/nC
T2831)×100,其中C
T2831為包含薑黃素衍生物的隱形眼鏡產品於波長280 nm~310 nm的平均穿透率T2831的數值,而nC
T2831則為一般不含薑黃素衍生物的隱形眼鏡產品於波長280 nm~310 nm的平均穿透率T2831的數值。第1控制組與第5實施例以及第1控制組與第7實施例的BE2831、BE3138、BE4146、BE4678、BE3878數值記錄於表六。
請參照第7圖至第11圖,第7圖係繪示本發明第8實施例與第2控制組於波長280 nm~310 nm的穿透率數據圖,第8圖係繪示本發明第8實施例與第2控制組於波長310 nm~380 nm的穿透率數據圖,第9圖係繪示本發明第8實施例與第2控制組於波長410 nm~460 nm的穿透率數據圖,第10圖係繪示本發明第8實施例與第2控制組於波長460 nm~780 nm的穿透率數據圖,而第11圖係繪示本發明第8實施例與第2控制組於波長380 nm~780 nm的穿透率數據圖。另外,為了更清楚呈現本發明之隱形眼鏡產品在其緩衝溶液添加抗氧化劑後克服因高溫高壓滅菌而破壞薑黃素衍生物之穩定性的效果,於此進一步提出未包含抗氧化劑之第2控制組,以和第8實施例進行比較說明,其中第2控制組的薑黃素衍生物具有如式(2)所示之結構,且Ccu = 0.05%。Please refer to Figures 7 to 11. Figure 7 shows the transmittance data of the eighth embodiment of the present invention and the second control group at a wavelength of 280 nm to 310 nm. Figure 8 shows the transmittance data of the eighth embodiment of the invention and the second control group. 8. The transmittance data graph of the eighth embodiment and the second control group at a wavelength of 310 nm to 380 nm. Figure 9 shows the transmittance of the eighth embodiment of the present invention and the second control group at a wavelength of 410 nm to 460 nm. Figure 10 is a graph showing the transmittance data of the eighth embodiment of the present invention and the second control group at a wavelength of 460 nm to 780 nm, and Figure 11 is a graph showing the eighth embodiment of the present invention and the second control group The transmittance data graph of the control group at a wavelength of 380 nm to 780 nm. In addition, in order to more clearly show the effect of adding antioxidants to the buffer solution of the contact lens product of the present invention to overcome the effect of destroying the stability of curcumin derivatives due to high temperature and high pressure sterilization, a second control group that does not contain antioxidants is further proposed here , To compare and illustrate with the 8th embodiment, wherein the curcumin derivative of the 2nd control group has the structure shown in formula (2), and Ccu=0.05%.
第2控制組與第8實施例的T2831、T3138、T4146、T4678、T3878於滅菌處理前一天(第-1天)、滅菌處理當天(第0天)、經滅菌處理後十天(第10天)以及經滅菌處理後十七天(第17天)的數值記錄於表七。
另外,於此更進一步根據第2控制組與第8實施例的T2831、T3138、T4146、T4678、T3878數值計算第8實施例於滅菌處理當天、經滅菌處理後十天以及經滅菌處理後十七天的BE2831、BE3138、BE4146、BE4678、BE3878的數值。第2控制組與第8實施例的BE2831、BE3138、BE4146、BE4678、BE3878數值記錄於表八。
<第9實施例至第12實施例><9th Example to 12th Example>
在第9實施例至第12實施例的隱形眼鏡產品中,隱形眼鏡的薑黃素衍生物具有如式(3)所示之結構,而關於第9實施例至第12實施例的薑黃素衍生物的詳細內容請參見表九。
在第9實施例至第12實施例的隱形眼鏡產品中,緩衝溶液的抗氧化劑係維生素C,濕潤劑為玻尿酸與海藻酸鈉,而關於第9實施例至第12實施例的Ccu、Cao、Cad、Ccu/Cao的數值請參見表十。
<第13實施例至第16實施例><Thirteenth to Sixteenth Examples>
在第13實施例至第16實施例的隱形眼鏡產品中,隱形眼鏡的薑黃素衍生物具有如式(4)所示之結構,而關於第13實施例至第16實施例的薑黃素衍生物的詳細內容請參見表十一。
在第13實施例至第16實施例的隱形眼鏡產品中,緩衝溶液的抗氧化劑係維生素C,濕潤劑為玻尿酸與海藻酸鈉,而關於第13實施例至第16實施例的Ccu、Cao、Cad、Ccu/Cao的數值請參見表十二。
<第17實施例至第20實施例><The 17th embodiment to the 20th embodiment>
在第17實施例至第20實施例的隱形眼鏡產品中,隱形眼鏡的薑黃素衍生物具有如式(5)所示之結構,而關於第17實施例至第20實施例的薑黃素衍生物的詳細內容請參見表十三。
在第17實施例至第20實施例的隱形眼鏡產品中,緩衝溶液的抗氧化劑係維生素C,濕潤劑為玻尿酸與海藻酸鈉,而關於第17實施例至第20實施例的Ccu、Cao、Cad、Ccu/Cao的數值請參見表十四。
<第21實施例至第24實施例><The twenty-first embodiment to the twenty-fourth embodiment>
在第21實施例至第24實施例的隱形眼鏡產品中,隱形眼鏡的薑黃素衍生物具有如式(6)所示之結構,而關於第21實施例至第24實施例的薑黃素衍生物的詳細內容請參見表十五。
在第21實施例至第24實施例的隱形眼鏡產品中,緩衝溶液的抗氧化劑係維生素C,濕潤劑為玻尿酸與海藻酸鈉,而關於第21實施例至第24實施例的Ccu、Cao、Cad、Ccu/Cao的數值請參見表十六。
<第25實施例至第28實施例><The twenty-fifth to twenty-eighth examples>
在第25實施例至第28實施例的隱形眼鏡產品中,隱形眼鏡的薑黃素衍生物具有如式(7)所示之結構,而關於第25實施例至第28實施例的薑黃素衍生物的詳細內容請參見表十七。
在第25實施例至第28實施例的隱形眼鏡產品中,緩衝溶液的抗氧化劑係維生素C,濕潤劑為玻尿酸與海藻酸鈉,而關於第25實施例至第28實施例的Ccu、Cao、Cad、Ccu/Cao的數值請參見表十八。
<第29實施例至第32實施例><The twenty-ninth embodiment to the thirty-second embodiment>
在第29實施例至第32實施例的隱形眼鏡產品中,隱形眼鏡的薑黃素衍生物具有如式(8)所示之結構,而關於第29實施例至第32實施例的薑黃素衍生物的詳細內容請參見表十九。
在第29實施例至第32實施例的隱形眼鏡產品中,緩衝溶液的抗氧化劑係維生素C,濕潤劑為玻尿酸與海藻酸鈉,而關於第29實施例至第32實施例的Ccu、Cao、Cad、Ccu/Cao的數值請參見表二十。
<第33實施例至第36實施例><The 33rd embodiment to the 36th embodiment>
在第33實施例至第36實施例的隱形眼鏡產品中,隱形眼鏡的薑黃素衍生物具有如式(9)所示之結構,而關於第33實施例至第36實施例的薑黃素衍生物的詳細內容請參見表二十一。
在第33實施例至第36實施例的隱形眼鏡產品中,緩衝溶液的抗氧化劑係維生素C,濕潤劑為玻尿酸與海藻酸鈉,而關於第33實施例至第36實施例的Ccu、Cao、Cad、Ccu/Cao的數值請參見表二十二。
<第37實施例至第40實施例><Thirty-seventh to fortieth embodiments>
在第37實施例至第40實施例的隱形眼鏡產品中,隱形眼鏡的薑黃素衍生物具有如式(10)所示之結構,而關於第37實施例至第40實施例的薑黃素衍生物的詳細內容請參見表二十三。
在第37實施例至第40實施例的隱形眼鏡產品中,緩衝溶液的抗氧化劑係維生素C,濕潤劑為玻尿酸與海藻酸鈉,而關於第37實施例至第40實施例的Ccu、Cao、Cad、Ccu/Cao的數值請參見表二十四。
<第41實施例至第44實施例><The 41st Embodiment to the 44th Embodiment>
在第41實施例至第44實施例的隱形眼鏡產品中,隱形眼鏡的薑黃素衍生物具有如式(11)所示之結構,而關於第41實施例至第44實施例的薑黃素衍生物的詳細內容請參見表二十五。
在第41實施例至第44實施例的隱形眼鏡產品中,緩衝溶液的抗氧化劑係維生素C,濕潤劑為玻尿酸與海藻酸鈉,而關於第41實施例至第44實施例的Ccu、Cao、Cad、Ccu/Cao的數值請參見表二十六。
<第45實施例至第48實施例><Forty-fifth to forty-eighth embodiments>
在第45實施例至第48實施例的隱形眼鏡產品中,隱形眼鏡的薑黃素衍生物具有如式(12)所示之結構,而關於第45實施例至第48實施例的薑黃素衍生物的詳細內容請參見表二十七。
在第45實施例至第48實施例的隱形眼鏡產品中,緩衝溶液的抗氧化劑係維生素C,濕潤劑為玻尿酸與海藻酸鈉,而關於第45實施例至第48實施例的Ccu、Cao、Cad、Ccu/Cao的數值請參見表二十八。
<第49實施例至第52實施例><49th to 52nd embodiment>
在第49實施例至第52實施例的隱形眼鏡產品中,隱形眼鏡的薑黃素衍生物具有如式(13)所示之結構,而關於第49實施例至第52實施例的薑黃素衍生物的詳細內容請參見表二十九。
在第49實施例至第52實施例的隱形眼鏡產品中,緩衝溶液的抗氧化劑係維生素C,濕潤劑為玻尿酸與海藻酸鈉,而關於第49實施例至第52實施例的Ccu、Cao、Cad、Ccu/Cao的數值請參見表三十。
<第53實施例至第56實施例><Fifty-third to fifty-sixth examples>
在第53實施例至第56實施例的隱形眼鏡產品中,隱形眼鏡的薑黃素衍生物具有如式(14)所示之結構,而關於第53實施例至第56實施例的薑黃素衍生物的詳細內容請參見表三十一。
在第53實施例至第56實施例的隱形眼鏡產品中,緩衝溶液的抗氧化劑係維生素C,濕潤劑為玻尿酸與海藻酸鈉,而關於第53實施例至第56實施例的Ccu、Cao、Cad、Ccu/Cao的數值請參見表三十二。
<第57實施例至第60實施例><Fifty-seventh to sixtieth embodiments>
在第57實施例至第60實施例的隱形眼鏡產品中,隱形眼鏡的薑黃素衍生物具有如式(15)所示之結構,而關於第57實施例至第60實施例的薑黃素衍生物的詳細內容請參見表三十三。
在第57實施例至第60實施例的隱形眼鏡產品中,緩衝溶液的抗氧化劑係維生素C,濕潤劑為玻尿酸與海藻酸鈉,而關於第57實施例至第60實施例的Ccu、Cao、Cad、Ccu/Cao的數值請參見表三十四。
雖然本發明已以實施方式揭露如上,然其並非用以限定本發明,任何熟習此技藝者,在不脫離本發明的精神和範圍內,當可作各種的更動與潤飾,因此本發明的保護範圍當視後附的申請專利範圍所界定者為準。Although the present invention has been disclosed above in terms of implementation, it is not intended to limit the present invention. Anyone skilled in the art can make various changes and modifications without departing from the spirit and scope of the present invention. Therefore, the protection of the present invention The scope shall be defined by the scope of the appended patent application.
100:隱形眼鏡產品 110:隱形眼鏡 120:緩衝溶液 100:Contact lens products 110: contact lenses 120: buffer solution
為讓本發明的上述和其他目的、特徵、優點與實施例能更明顯易懂,所附圖式的說明如下: 第1圖係繪示本發明一實施方式的一種隱形眼鏡產品的示意圖; 第2圖係繪示本發明第5實施例、第7實施例與第1控制組於波長280 nm~310 nm的穿透率數據圖; 第3圖係繪示本發明第5實施例、第7實施例與第1控制組於波長310 nm~380 nm的穿透率數據圖; 第4圖係繪示本發明第5實施例、第7實施例與第1控制組於波長410 nm~460 nm的穿透率數據圖; 第5圖係繪示本發明第5實施例、第7實施例與第1控制組於波長460 nm~780 nm的穿透率數據圖; 第6圖係繪示本發明第5實施例、第7實施例與第1控制組於波長380 nm~780 nm的穿透率數據圖; 第7圖係繪示本發明第8實施例與第2控制組於波長280 nm~310 nm的穿透率數據圖; 第8圖係繪示本發明第8實施例與第2控制組於波長310 nm~380 nm的穿透率數據圖; 第9圖係繪示本發明第8實施例與第2控制組於波長410 nm~460 nm的穿透率數據圖; 第10圖係繪示本發明第8實施例與第2控制組於波長460 nm~780 nm的穿透率數據圖;以及 第11圖係繪示本發明第8實施例與第2控制組於波長380 nm~780 nm的穿透率數據圖。 In order to make the above and other objects, features, advantages and embodiments of the present invention more obvious and understandable, the accompanying drawings are described as follows: Figure 1 is a schematic diagram illustrating a contact lens product according to an embodiment of the present invention; Figure 2 is a graph showing the transmittance data of the fifth embodiment, the seventh embodiment and the first control group of the present invention at a wavelength of 280 nm to 310 nm; Figure 3 is a graph showing the transmittance data of the fifth embodiment, the seventh embodiment and the first control group of the present invention at a wavelength of 310 nm to 380 nm; Figure 4 is a graph showing the transmittance data of the fifth embodiment, the seventh embodiment and the first control group of the present invention at a wavelength of 410 nm to 460 nm; Figure 5 is a graph showing the transmittance data of the fifth embodiment, the seventh embodiment and the first control group of the present invention at a wavelength of 460 nm to 780 nm; Figure 6 is a graph showing the transmittance data of the fifth embodiment, the seventh embodiment and the first control group of the present invention at a wavelength of 380 nm to 780 nm; Figure 7 is a graph showing the transmittance data of the eighth embodiment of the present invention and the second control group at a wavelength of 280 nm to 310 nm; Figure 8 is a graph showing the transmittance data of the eighth embodiment of the present invention and the second control group at a wavelength of 310 nm to 380 nm; Figure 9 is a diagram showing the transmittance data of the eighth embodiment of the present invention and the second control group at a wavelength of 410 nm to 460 nm; Figure 10 is a graph showing the transmittance data of the eighth embodiment of the present invention and the second control group at a wavelength of 460 nm to 780 nm; and Fig. 11 is a diagram showing the transmittance data of the eighth embodiment of the present invention and the second control group at a wavelength of 380 nm to 780 nm.
100:隱形眼鏡產品 100:Contact lens products
110:隱形眼鏡 110: contact lenses
120:緩衝溶液 120: buffer solution
Claims (17)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TW111103008A TWI808627B (en) | 2021-04-01 | 2021-04-01 | Contact lens product |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TW111103008A TWI808627B (en) | 2021-04-01 | 2021-04-01 | Contact lens product |
Publications (2)
Publication Number | Publication Date |
---|---|
TW202239386A true TW202239386A (en) | 2022-10-16 |
TWI808627B TWI808627B (en) | 2023-07-11 |
Family
ID=85460359
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW111103008A TWI808627B (en) | 2021-04-01 | 2021-04-01 | Contact lens product |
Country Status (1)
Country | Link |
---|---|
TW (1) | TWI808627B (en) |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2585632T3 (en) * | 2010-07-05 | 2016-10-07 | Dave, Jagrat Natavar | Ophthalmic reflective-diffractive device and compositions useful for manufacturing it |
TW202009013A (en) * | 2018-08-14 | 2020-03-01 | 優你康光學股份有限公司 | Contact lenses with functional components and products thereof |
US11260612B2 (en) * | 2018-11-21 | 2022-03-01 | University Of Florida Research Foundation, Inc. | Methods and compositions for pigmented hydrogels and contact lenses |
-
2021
- 2021-04-01 TW TW111103008A patent/TWI808627B/en active
Also Published As
Publication number | Publication date |
---|---|
TWI808627B (en) | 2023-07-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6316918B2 (en) | Contact lenses that reduce indoor glare | |
TWI587017B (en) | Photochromic hydrogel contact lens and the method for making the same | |
TWI587022B (en) | Toric contact lens and method for making the same | |
US10578889B2 (en) | Contact lens product | |
US11724471B2 (en) | Methods for the manufacture of photoabsorbing contact lenses and photoabsorbing contact lenses produced thereby | |
CN106810640A (en) | Glue constituent and glue eyeglass | |
TWI663431B (en) | Contact lens product | |
TWI741684B (en) | Contact lens product | |
TWI808627B (en) | Contact lens product | |
TWI758153B (en) | Contact lens product | |
TW202337410A (en) | Contact lens product | |
TWI702438B (en) | Contact lens product | |
RU2779564C1 (en) | Methods for manufacture of photo-absorbing contact lenses, and photo-absorbing contact lenses obtained by means of them | |
TW202132866A (en) | Contact lens and contact lens product |